Articles related to ADVERSE EVENTS

Nine oncology nurses interviewed at a Swedish hospital described opportunities for individualized home-based antineoplastic treatment alongside concerns about adverse reactions, solitary practice, and resources. The qualitative study did not evaluate patient outcomes or comparative safety.

A review identified 15 reports of Wernicke encephalopathy among patients receiving GLP-1 therapies, most accompanied by poor intake, vomiting, weight loss, or malnutrition, highlighting a rare safety signal without establishing drug-related causality.

Older adults with advanced or metastatic urothelial carcinoma treated with enfortumab vedotin experienced substantially higher rates of severe toxicity and treatment discontinuation than younger patients, while survival outcomes appeared similar across age groups.

In SCRaTCH-OFO, live birth rates were 64% with endometrial scratching and 57% without it among patients with unexplained infertility and favorable natural-conception prognosis. The difference was not statistically significant, and enrollment fell short.

Mayim Bialik reports prolonged gastrointestinal symptoms after one dose of an unnamed GLP-1 medication taken for autoimmune symptoms. Her account describes individual intolerance, not the frequency of severe reactions or evidence of autoimmune benefit.

A single-case report describes SAFE-SEAL, a percutaneous bailout technique that restored hemostasis after failure of hybrid femoral closure during transfemoral TAVR, suggesting a potential alternative to more invasive rescue strategies when guidewire access has been lost.